首页 › 基金 › SR ONE CAPITAL MANAGEMENT, LP › MLYS
SR ONE CAPITAL MANAGEMENT, LP 对 MLYS 的持仓历史
MINERALYS THERAPEUTICS INC · 医疗保健
SR ONE CAPITAL MANAGEMENT, LP 在 Q3 2026 的 13F 申报中披露持有 MLYS(MINERALYS THERAPEUTICS INC)1,563,966 股,市值约 US$39.3M,约占其申报组合的 3.42%,在其申报持仓中市值排名第 9 位。 SR ONE CAPITAL MANAGEMENT, LP 最近 13 个申报季度中有 13 个季度披露了 MLYS 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
SR ONE CAPITAL MANAGEMENT, LP 对 MLYS 的持仓演变
SR ONE CAPITAL MANAGEMENT, LP 于 Q3 2023 首次披露 MLYS 持仓:1,794,600 股(约 US$17.1M)。 该持仓在 Q3 2025 达到峰值 2,113,933 股,市值约 US$80.2M。 在 13 次申报中,SR ONE CAPITAL MANAGEMENT, LP 2 次增持、2 次减持、8 次保持不变。 最近一期申报(Q3 2026)显示持股 1,563,966 股、市值约 US$39.3M。 持仓曾出现大幅变动:Q1 2025 增持约 55% (随后一个季度股价下跌 15%)、Q3 2025 减持约 32% (随后一个季度股价下跌 4%)、Q4 2025 减持约 26% (随后一个季度股价下跌 25%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 1.79M | $17.07M | 新进 |
| Q4 2023 | 1.79M | $15.43M | 持有 |
| Q1 2024 | 2.02M | $26.04M | 增持 |
| Q2 2024 | 2.02M | $23.60M | 持有 |
| Q3 2024 | 2.02M | $24.42M | 持有 |
| Q4 2024 | 2.02M | $24.83M | 持有 |
| Q1 2025 | 3.13M | $49.67M | 增持 |
| Q2 2025 | 3.13M | $42.32M | 持有 |
| Q3 2025 | 2.11M | $80.16M | 减持 |
| Q4 2025 | 1.56M | $56.76M | 减持 |
| Q1 2026 | 1.56M | $42.37M | 持有 |
| Q2 2026 | 1.56M | $42.20M | 持有 |
| Q3 2026 | 1.56M | $39.30M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 MLYS 与 13F 数据
MLYS(MINERALYS THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 49 只申报持有 MLYS,申报仓位最大的包括:Catalys Pacific, LLC (US$196.0M), RA CAPITAL MANAGEMENT, L.P. (US$193.3M), Samsara BioCapital, LLC (US$147.5M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 MLYS 的基金
- Catalys Pacific, LLC 7.80M 股 · $196.00M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 7.69M 股 · $193.32M · Q3 2026
- Samsara BioCapital, LLC 5.87M 股 · $147.54M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.96M 股 · $99.46M · Q3 2026
- Laurion Capital Management LP 2.48M 股 · $62.37M · Q3 2026
- ARMISTICE CAPITAL, LLC 1.60M 股 · $40.21M · Q3 2026
- Andera Partners 1.59M 股 · $40.00M · Q3 2026
- ORBIMED ADVISORS LLC 1.45M 股 · $36.55M · Q3 2026
- SPHERA FUNDS MANAGEMENT LTD. 1.32M 股 · $33.22M · Q3 2026
- Ghisallo Capital Management LLC 1.12M 股 · $28.27M · Q3 2026
- MONTANOVA CAPITAL, LLC 1.10M 股 · $27.67M · Q3 2026
- Troluce Capital Advisors LLC 1.06M 股 · $26.75M · Q3 2026
更多关于 SR ONE CAPITAL MANAGEMENT, LP
常见问题
How long has SR ONE CAPITAL MANAGEMENT, LP held MLYS?
SR ONE CAPITAL MANAGEMENT, LP has disclosed MLYS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is SR ONE CAPITAL MANAGEMENT, LP's current position in MLYS?
As of Q3 2026, SR ONE CAPITAL MANAGEMENT, LP holds 1.56M shares of MLYS (MINERALYS THERAPEUTICS INC), valued at $39.30M, representing 3.42% of its reported portfolio and ranking #9.
Has SR ONE CAPITAL MANAGEMENT, LP been buying or selling MLYS?
In the latest 13F filing (Q3 2026), SR ONE CAPITAL MANAGEMENT, LP held unchanged its position in MLYS. The position peaked in Q3 2025 at 2.11M shares.
Which other funds hold MLYS?
Other major institutional holders of MLYS include Catalys Pacific, LLC, RA CAPITAL MANAGEMENT, L.P., Samsara BioCapital, LLC, among 49 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.